1. Dubey JP. Toxoplasmosis–a waterborne zoonosis. Vet Parasitol. 2004;126(1-2):57-72.
2. Dubey J. Advances in the life cycle of Toxoplasma gondii. Int J Parasitol. 1998;28(7):1019-24.
3. Dubey JP. The history and life cycle of Toxoplasma gondii. In: Toxoplasma gondii. Elsevier; 2020. p. 1-19.
4. Dickerson FB, Stallings CR, Boronow JJ, Origoni AE, Yolken RH. A double-blind trial of adjunctive azithromycin in individuals with schizophrenia who are seropositive for Toxoplasma gondii. Schizophr Res. 2009;112(1-3):198-9.
5. Fuglewicz AJ, Piotrowski P, Stodolak A. Relationship between toxoplasmosis and schizophrenia: a review. Adv Clin Exp Med. 2017;26(6):1031-6.
6. Hrdá Š, Votýpka J, Kodym P, Flegr J. Transient nature of Toxoplasma gondii-induced behavioral changes in mice. J Parasitol. 2000;86(4):657-63.
7. Firouzeh N, Ziaali N, Sheibani V, et al. Chronic Toxoplasma gondii infection potentiates Parkinson’s disease course in mice model. Iran J Parasitol. 2021;16(4):527-537.
8. Gormley PD, Pavesio CE, Minnasian D, Lightman S. Effects of drug therapy on Toxoplasma cysts in an animal model of acute and chronic disease. Invest Ophthalmol Vis Sci. 1998;39(7):1171-5.
9. Walker MJ. Opportunistic infections studies update. NIAID AIDS Agenda. 1995:6-7.
10. Araujo F, Shepard R, Remington J. In vivo activity of the macrolide antibiotics azithromycin, roxithromycin and spiramycin against Toxoplasma gondii. Eur J Clin Microbiol Infect Dis. 1991;10:519-24.
11. Araujo FG, Guptill DR, Remington JS. Azithromycin, a macrolide antibiotic with potent activity against Toxoplasma gondii. Antimicrob Agents Chemother. 1988;32(5):755-7.
12. Araujo FG, Shepard RM, Remington JS. In vivo activity of the macrolide antibiotics azithromycin, roxithromycin and spiramycin against Toxoplasma gondii. Eur J Clin Microbiol Infect Dis. 1991;10(6):519-24.
13. Değerli K, Kilimcioğlu AA, Kurt O, Tamay AT, Ozbilgin A. Efficacy of azithromycin in a murine toxoplasmosis model, employing a Toxoplasma gondii strain from Turkey. Acta Trop. 2003;88(1):45-50.
14. Chang HR. The potential role of azithromycin in the treatment or prophylaxis of toxoplasmosis. Int J STD AIDS. 1996;7 Suppl 1:18-22.
15. Caprifico AE, Foot PJ, Polycarpou E, Calabrese G. Overcoming the blood-brain barrier: Functionalised chitosan nanocarriers. Pharmaceutics. 2020; 12(11):1013.
16. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2003;55(3):329-47.
17. Assolini JP, Concato VM, Gonçalves MD, et al. Nanomedicine advances in toxoplasmosis: diagnostic, treatment, and vaccine applications. Parasitol Res. 2017;116:1603-15.
18. Briones E, Isabel Colino C, Lanao JM. Delivery systems to increase the selectivity of antibiotics in phagocytic cells. J Control Release. 2008;125(3):210-27.
19. Soheili S, Mandegar E, Moradikhah F, Doosti-Telgerd M, Javar HA. Experimental and numerical studies on microfluidic preparation and engineering of chitosan nanoparticles. J Drug Deliv Sci Technol. 2021;61:102268.
20. Chai Y, Wang Y, Li B, Qi W, Su R, He Z. Microfluidic synthesis of lignin/chitosan nanoparticles for the pH-responsive delivery of anticancer drugs. Langmuir. 2021;37(23):7219-26.
21. Cheraghipour K, Masoori L, Ezzatkhah F, et al. Effect of chitosan on Toxoplasma gondii infection: A systematic review. Parasite Epidemiol Control. 2020;11:e00189.
22. Etewa SE, El-Maaty DAA, Hamza RS, et al. Assessment of spiramycin-loaded chitosan nanoparticles treatment on acute and chronic toxoplasmosis in mice. J Parasit Dis. 2018;42:102-13.
23. El-Gendy AML, Mohammed MAA, Ghallab MMI, Aziz MOA, Ibrahim SM. Therapeutic effect of chitosan nanoparticles and metronidazole in treatment of experimentally giardiasis infected hamsters. Iran J Parasitol. 2021;16(1):32-42.
24. Hagras NA-e, Allam AF, Farag HF, et al. Successful treatment of acute experimental toxoplasmosis by spiramycin-loaded chitosan nanoparticles. Exp Parasitol. 2019;204:107717.
25. Teimouri A, Azami SJ, Keshavarz H, et al. Anti-Toxoplasma activity of various molecular weights and concentrations of chitosan nanoparticles on tachyzoites of RH strain. Int J Nanomedicine. 2018;13:1341-51.
26. Saraei M, Samadzadeh N, Khoeini J, et al. In vivo anti-Toxoplasma activity of aripiprazole. Iran J Basic Med Sci. 2015;18(9):938-41.
27. Saraei M, Ghaderi Y, Mosavi T, et al. The effect of fluphenazine and thioridazine on Toxoplasma gondii in vivo. Iran J Parasitol. 2016;11(2):226-231.
28. Mirhosseini M, Yazdani N, Dehghan Hamdan A. Investigation of antimicrobial properties of chitosan– ZnO nanocomposite. Razi J Med Sci. 2016;23(147):104-14.
29. Abd Elgawad H, Alhusseiny SM, Taman A, et al. Biological evaluation of newly synthesized quinoline–based compound PPQ-8 in acute and chronic toxoplasmosis: An experimental study. Exp Parasitol. 2019;206:107756.
30. Teimouri A, Motevalli Haghi A, Nateghpour M, et al. Antimalarial efficacy of low molecular weight chitosan against Plasmodium berghei infection in mice. J Vector Borne Dis. 2016;53(4):312-316.
31. Gaafar MR, Mady RF, . Diab RG, Shalaby ThI. Chitosan and silver nanoparticles: Promising anti-toxoplasma agents. Exp Parasitol. 2014; 143:30-38.
32. Rahimi Esboei B, Keighobadi M, Ziaei Hezarjaribi H, et al. Promising in vitro anti-Toxoplasma gondii effects of commercial chitosan. Infect Disord Drug Targets. 2021; 21(1):151-155.
33. Raouf M, Essa S, El Achy S, et al. Evaluation of Combined Ciprofloxacin and azithromycin free and nano formulations to control biofilm producing Pseudomonas aeruginosa isolated from burn wounds. Indian J Med Microbiol. 2021;39(1):81-7.
34. Jonassen H, Kjøniksen A-L, Hiorth M. Stability of chitosan nanoparticles cross-linked with tripolyphosphate. Bio-macromolecules. 2012;13(11):3747-56.
35. Habibizadeh M, Nadri S, Fattahi A, et al. Surface modification of neurotrophin-3 loaded PCL/chitosan nanofiber/net by alginate hydrogel microlayer for enhanced biocompatibility in neural tissue engineering. J Biomed Mater Res A. 2021;109(11):2237-54.
36. Dumas JL, Chang R, Mermillod B, et al. Evaluation of the efficacy of prolonged administration of azithromycin in a murine model of chronic toxoplasmosis. J Antimicrob Chemother. 1994;34(1):111-8.
37. Asgari Q, Keshavarz H, Shojaee S, et al. In vitro and in vivo potential of RH strain of Toxoplasma gondii (Type I) in tissue cyst forming. Iran J Parasitol. 2013;8(3):367-75.
38. Salimi M, Shojaee S, Keshavarz H, Mohebali M. Cyst formation from virulent RH strain of Toxoplasma gondii tachyzoite: in vitro cultivation. Iran J Parasitol. 2016;11(1):81-5.
39. Djurković-Djaković O, Milenković V, Nikolić A, et al. Efficacy of atovaquone combined with clindamycin against murine infection with a cystogenic (Me49) strain of Toxoplasma gondii. J Antimicrob Chemother. 2002;50(6):981-7.
40. Ferreira RA, Oliveira AB, Ribeiro MF, et al. Toxoplasma gondii: in vitro and in vivo activities of the hydroxynaphthoquinone 2-hydroxy-3-(1'-propen-3-phenyl)-1, 4-naphthoquinone alone or combined with sulfadiazine. Exp Parasitol. 2006; 113(2):125-9.
41. Shu H, Jiang L. Effect of garlicin and minocycline on the cyst formation of Toxoplasma gondii in mice. Chinese J Zoonoses. 2002;18(1):100-1.
42. Ferguson D, Huskinson-Mark J, Araujo F, Remington J. An ultrastructural study of the effect of treatment with atovaquone in brains of mice chronically infected with the ME49 strain of Toxoplasma gondii. Int J Exp Pathol. 1994;75(2):111-6.
43. Rutaganira FU, Barks J, Dhason MS, et al. Inhibition of calcium dependent protein kinase 1 (CDPK1) by pyrazolopyrimidine analogs decreases establishment and reoccurrence of central nervous system disease by Toxoplasma gondii. J Med Chem. 2017;60(24):9976-89.
44. Mahmoud DM, Mahmoud MS, Ezz-El-Din HM, et al. Artesunate effect on RH virulent and ME49 non-virulent strains of Toxoplasma gondii: in vitro and in vivo experimental studies. Sci Parasitol. 2016;17:83-92.
45. Chew WK, Segarra I, Ambu S, Mak JW. Significant reduction of brain cysts caused by Toxoplasma gondii after treatment with spiramycin coadministered with metronidazole in a mouse model of chronic toxoplasmosis. Antimicrob Agents Chemother. 2012;56(4):1762-8.
46. Ghaffarifar F, Pour MA, Sharifi Z, Asl AD, Al-Kawaz E. The effect of vitamin D3 alone and mixed with IFN-γ on tachyzoites of Toxoplasma gondii (RH strain) proliferation and nitric oxide (NO) production in infected macrophages of BALB/C mice. Iran J Parasitol. 2010;5(3):48-56.